Autolus Therapeutics plc

3.46+0.0800+2.37%Vol 267.37K1Y Perf -43.48%
Aug 11th, 2022 16:00 DELAYED
BID3.37 ASK3.66
Open3.41 Previous Close3.38
Pre-Market- After-Market3.60
 - -  0.14 4.05%
Target Price
10.25 
Analyst Rating
Strong Buy 1.40
Potential %
196.24 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★+     53.63
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★+     49.62
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
25.25 
Earnings Rating
Strong Buy
Market Cap314.55M 
Earnings Date
4th Aug 2022
Alpha-0.04 Standard Deviation0.20
Beta1.45 

Today's Price Range

3.243.69

52W Range

1.967.90

5 Year PE Ratio Range

-42.60-3.60

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
-0.57%
1 Month
15.72%
3 Months
44.17%
6 Months
-23.62%
1 Year
-43.48%
3 Years
-64.66%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AUTL3.460.08002.37
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
-
-7 158.30
-6 777.90
-
-
RevenueValueIndustryS&P 500US Markets
823.00K
0.01
-11.66
-
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.42-0.46-9.52
Q01 2022-0.51-0.4119.61
Q04 2021-0.49-0.51-4.08
Q03 2021-0.50-0.476.00
Q02 2021-0.50-0.476.00
Q01 2021-0.62-0.5314.52
Q04 2020-0.75-0.82-9.33
Q03 2020-0.66-0.72-9.09
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.4214.29Positive
9/2022 QR-0.4310.42Positive
12/2022 FY-1.7113.64Positive
12/2023 FY-1.799.60Positive
Next Report Date-
Estimated EPS Next Report-0.42
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume267.37K
Shares Outstanding90.91K
Shares Float90.92M
Trades Count1.14K
Dollar Volume937.58K
Avg. Volume158.55K
Avg. Weekly Volume192.90K
Avg. Monthly Volume120.88K
Avg. Quarterly Volume161.87K

Autolus Therapeutics plc (NASDAQ: AUTL) stock closed at 3.46 per share at the end of the most recent trading day (a 2.37% change compared to the prior day closing price) with a volume of 267.37K shares and market capitalization of 314.55M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 298 people. Autolus Therapeutics plc CEO is Christian Itin.

The one-year performance of Autolus Therapeutics plc stock is -43.48%, while year-to-date (YTD) performance is -33.33%. AUTL stock has a five-year performance of %. Its 52-week range is between 1.96 and 7.9, which gives AUTL stock a 52-week price range ratio of 25.25%

Autolus Therapeutics plc currently has a PE ratio of -1.60, a price-to-book (PB) ratio of 0.98, a price-to-sale (PS) ratio of 323.69, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -42.03%, a ROC of -46.84% and a ROE of -52.67%. The company’s profit margin is -%, its EBITDA margin is -6 777.90%, and its revenue ttm is $823.00 Thousand , which makes it $0.01 revenue per share.

Of the last four earnings reports from Autolus Therapeutics plc, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.42 for the next earnings report. Autolus Therapeutics plc’s next earnings report date is -.

The consensus rating of Wall Street analysts for Autolus Therapeutics plc is Strong Buy (1.4), with a target price of $10.25, which is +196.24% compared to the current price. The earnings rating for Autolus Therapeutics plc stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Autolus Therapeutics plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Autolus Therapeutics plc has a Buy technical analysis rating based on Technical Indicators (ADX : 13.90, ATR14 : 0.29, CCI20 : 140.51, Chaikin Money Flow : -0.15, MACD : 0.15, Money Flow Index : 83.56, ROC : 16.11, RSI : 60.36, STOCH (14,3) : 75.44, STOCH RSI : 0.91, UO : 53.46, Williams %R : -24.56), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Autolus Therapeutics plc in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (80.00 %)
4 (80.00 %)
4 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
1 (16.67 %)
Hold
1 (20.00 %)
1 (20.00 %)
1 (16.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.40
Strong Buy
1.40
Strong Buy
1.50

Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company. It is engaged in the development of next-generation programmed T cell therapies for the treatment of cancer. The company's pipeline includes AUTO1, AUTO2, AUTO3, AUTO4, and others.

CEO: Christian Itin

Telephone: +44 2038296230

Address: 58 Wood Lane, London W12 7RZ, , GB

Number of employees: 298

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

82%18%

Bearish Bullish

79%21%

Bearish Bullish

62%38%


News

Stocktwits